| Literature DB >> 31947799 |
Silvia Bittner Fialová1, Elena Kurin1, Eva Trajčíková1, Lucia Jánošová2, Ivana Šušaníková1, Daniela Tekeľová1, Milan Nagy1, Pavel Mučaji1.
Abstract
Unlike its aerial parts, the underground parts of Mentha have so far been studied only marginally. By examining the polyphenolic fingerprint, the antioxidant efficacy and the mutual antioxidant behaviour of mixtures of mint rhizomes, our study presents a modest contribution to addressing this gap. Firstly, we examined the composition of the mint rhizomes: Mentha × piperita cv. 'Perpeta' (MPP), M. longifolia (ML), and M. × villosa cv. 'Snežna' (MVS). Our LC-MS-DAD analysis revealed the presence of ten compounds belonging to groups of phenolic acids and flavonoids, of which the rosmarinic acid (RA) and lithospermic were most strongly represented. Secondly, we evaluated the antioxidant activity of rhizome infusions by DPPH and ABTS and on NIH/3T3 cell lines by DCFH-DA. Thirdly, we determined, examined, and explained the mutual interactions of rhizome infusions mixtures. While most of the combinations acted additive, synergy was observed in ternary infusion mixtures. The synergic action was also detected in the combination of MPP rhizome infusion and RA in the DCFH-DA test. The combinations of mint rhizomes and rosmarinic acid displayed a high dose-reduction index. This leads to beneficial dose reduction at a given antioxidant effect level in mixtures, compared to the dose of the parts used alone. So far, the pharmaceutical and food industry has not used mint rhizomes in commercial products. Hence, our study draws attention to further applications of the Mentha rhizomes as a valuable alternative source of natural antioxidants.Entities:
Keywords: Mentha rhizomes; antioxidant activity; interaction study; lithospermic acid; rosmarinic acid
Year: 2020 PMID: 31947799 PMCID: PMC6983171 DOI: 10.3390/molecules25010200
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Polar phenolic compounds in infusions of Mentha rhizomes, their corresponding retention times (tR), molecular ions [M − H], and MS2 fragments in LC-MS analysis.
| Peak | Compound | tR (min) | [M − H]− ( | MS2 (20 eV) ( |
|---|---|---|---|---|
| 1. | Protocatechuic aldehyd | 17.59 | 137 | |
| 2. | Caffeic acid | 26.67 | 179 | |
| 3. | Eriodictyol-7- | 35.29 | 595 | 287 |
| 4. | 2-(3,4-dihydroxyphenyl)ethyl ester of Salvianolic acid D | 41.14 | 553 | 373, 329, 197, 179 |
| 5. | Rosmarinic acid | 45.28 | 359 | 197, 161 |
| 6. | Hesperetin-7- | 47.84 | 609 | 301 |
| 7. | Salvianolic acid B | 48.16 | 717 | 519, 321, 179 |
| 8. | Lithospermic acid | 48.64 | 537 | 359 |
| 9. | Salvianolic acid A | 49.83 | 493 | 359, 313 |
| 10. | Caffeic acid tetramer | 50.30 | 715 | 535, 491 |
| 11. | Luteolin-7- | 50.89 | 593 | 285 |
Quantitative abundance of polar phenolic compounds in infusions of Mentha rhizomes (μg/mL).
| Compound | Mass Concentration (μg/mL) * ± | ||
|---|---|---|---|
|
| |||
| Protocatechuic aldehyde a | <LOQ | nd | <LOQ |
| Caffeic acid b | 2.8 ± 0.02 | nd | <LOQ |
| Eriodictyol-7- | nd | 14.4 ± 0.82 | nd |
| 2-(3,4-dihydroxyphenyl)ethyl ester of Salvianolic acid D d | 7.1 ± 3.18 | nd | 4.8 ± 0.04 |
| Rosmarinic acid d | 115.9 ± 0.29 | 54.0 ± 0.14 | 55.7 ± 0.11 |
| Hesperetin-7- | 19.3 ± 0.29 | nd | 8.9 ± 0.45 |
| Salvianolic acid B d | 14.6 ± 0.07 | 21.3 ± 0.09 | 9.0 ± 0.01 |
| Lithospermic acid d | 25.8 ± 0.06 | 82.1 ± 0.12 | 20.6 ± 0.10 |
| Salvianolic acid A d | nd | nd | 4.0 ± 0.16 |
| Caffeic acid tetramer d | nd | nd | 10.7 ± 0.10 |
| Luteolin-7- | <LOD | nd | 9.1 ± 0.28 |
| Total flavonoids | 20.8 ± 0.69 | 14.4 ± 0.82 | 18.0 ± 0.17 |
| Total phenolic acids | 166.7 ± 1.12 | 157.4 ± 0.35 | 106.3 ± 0.59 |
| Total phenolics | 187.5 ± 0.43 | 171.8 ± 0.47 | 124.3 ± 0.41 |
* Values (μg/mL liquid infusion) are presented as means ± standard deviation (n = 3), external standards: protocatechuic aldehyde a; caffeic acid b; luteolin-7-O-glucoside c; rosmarinic acid d; LOQ-limit of quantification; LOD—limit of detection.
Figure 1Dose-dependent DPPH and ABTS radical inhibition of single mint extracts and rosmarinic acid. The bars represent mean ± SD, n = 4.
Interaction analysis of mutual mint infusions and mint infusions/rosmarinic acid combinations in DPPH and ABTS assays: IC50, CI, and DRI values of equal mass concentration infusions combinations at 50% inhibition dose level.
| Infusions Combination a | IC50 (μg/mL) b |
| CI c | SDA d | Combined Effect | DRI e | |
|---|---|---|---|---|---|---|---|
| DPPH | MPP:ML | 0.98 | 0.97 | ±0.02 | nearly additive | 2.19:1.96 | |
| MPP:MVS | 0.99 | 1.01 | ±0.01 | nearly additive | 1.70:2.37 | ||
| ML:MVS | 0.97 | 1.09 | ±0.02 | nearly additive | 1.50:2.33 | ||
| MPP:ML:MVS | 0.99 | 1.05 | ±0.01 | nearly additive | 2.69:2.41:3.74 | ||
| MPP:RA | 0.98 | 1.78 | ±0.03 | antagonism | 7.60:0.61 | ||
| ML:RA | 0.98 | 2.63 | ±0.05 | antagonism | 4.61:0.41 | ||
| MVS:RA | 0.98 | 1.24 | ±0.02 | moderate antagonism | 14.80:0.85 | ||
| ABTS | MPP:ML | 0.98 | 0.91 | ±0.03 | nearly additive | 2.52:1.95 | |
| MPP:MVS | 0.98 | 1.34 | ±0.04 | moderate antagonism | 1.25:1.85 | ||
| ML:MVS | 0.98 | 1.04 | ±0.03 | nearly additive | 1.46:2.79 | ||
| MPP:ML:MVS | 0.96 | 0.89 | ±0.03 | slight synergism | 3.32:2.57:4.93 | ||
| MPP:RA | 0.98 | 1.80 | ±0.03 | antagonism | 15.09:0.58 | ||
| ML:RA | 0.99 | 2.24 | ±0.03 | antagonism | 9.51:0.47 | ||
| MVS:RA | 0.98 | 1.85 | ±0.03 | antagonism | 21.60:0.56 |
a MPP—Mentha × piperita cv. ‘Perpeta’; ML—Mentha longifolia; MVS—Mentha × villosa cv. ‘Snežná’; RA—rosmarinic acid. b Median inhibitory activities IC50 (μg/mL) of the equal mass concentration infusions combinations and in bracket their single infusion/compound IC50 level. c CI—combination index, a quantitative measure based on the mass-action law of the degree of drug interaction in terms of synergism (CI < 1) and antagonism (CI > 1) for a given endpoint of the effect measurement. The combined effect is evaluated according to Chou (2006). d SDA-sequential deletion analysis, iterative sequential deletion of one dose (or concentration) of a drug at a time for repetitive CI calculations. e DRI represents the order of magnitude (fold) of dose reduction that is allowed in combination for a given degree of effect as compared with the dose of each drug alone.
Figure 2IC50 (µg/mL) of Mentha rhizomes extracts (MPP—Mentha × piperita cv. ‘Perpeta’, ML—Mentha longifolia, MVS—Mentha × villosa cv. ‘Snežná’, RA—rosmarinic acid, and their mixtures in the intracellular ROS inhibition in NIH/3T3 cells, using DCFH-DA assay. IC50 and r values (MPP = 0.99, ML = 0.99, MVS = 0.98, MPP:RA = 0.97, ML:RA = 0.95, MVS:RA = 0.96) were calculated by using CompuSyn software, n = 4. r value: the conformity parameter for the goodness of fit to the median-effect principle (MEP) of the mass-action law. It is the linear correlation coefficient of the median effect plot, where r 1 indicates perfect conformity.
Figure 3Illustrative isobologram of MPP:RA mixture at 50% effect dose level, (MPP—Mentha × piperita cv. ‘Perpeta’; RA—rosmarinic acid).
Interaction analysis of mutual mint infusions and mint extracts/rosmarinic acid combinations in DCFH-DA assays: IC50, CI, and DRI values of equal mass concentration infusions combinations at 50% inhibition dose level.
| Infusions Combination a | IC50 (μg/mL) b |
| CI c | SDA d | Combined Effect | DRI e | |
|---|---|---|---|---|---|---|---|
| DCFH-DA | MPP:RA | 0.64 | 0.97 | 0.89 | ±0.04 | slight synergism | 28.74:1.17 |
| ML:RA | 1.81 | 0.95 | 2.49 | ±0.10 | antagonism | 14.77:0.41 | |
| MVS:RA | 1.42 | 0.96 | 1.94 | ±0.08 | antagonism | 25.79:0.53 |
a MPP—Mentha × piperita cv. ‘Perpeta’; ML—Mentha longifolia; MVS—Mentha × villosa cv. ‘Snežná’; RA—rosmarinic acid. b Median inhibitory activities IC50 (μg/mL) of the equal mass concentration infusions combinations and in bracket their single infusion/compound IC50 level. c CI—combination index, a quantitative measure based on the mass-action law of the degree of drug interaction in terms of synergism (CI < 1) and antagonism (CI > 1) for a given endpoint of the effect measurement. The combined effect is evaluated according to Chou (2006). d SDA-sequential deletion analysis, iterative sequential deletion of one dose (or concentration) of a drug at a time for repetitive CI calculations. e DRI represents the order of magnitude (fold) of dose reduction that is allowed in combination for a given degree of effect as compared with the dose of each drug alone.
The scales of combined effects by using the log(CI) grading.
| Range of Combination Index | Description | |
|---|---|---|
|
| <0.1 | Very strong synergism |
| 0.1–0.3 | Strong synergism | |
| 0.3–0.7 | Synergism | |
| 0.7–0.85 | Moderate synergism | |
| 0.85–0.90 | Slight synergism | |
| 0.90–1.10 | Nearly additive | |
|
| 1.10–1.20 | Slight antagonism |
| 1.20–1.45 | Moderate antagonism | |
| 1.45–3.3 | Antagonism | |
| 3.3–10 | Strong antagonism | |
| ˃10 | Very strong antagonism |